相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
5
83.3%
Unknown
1
16.7%
暂无批准数据
- Ondine Biomedical's Steriwave photodisinfection technology demonstrated 99.9% eradication of Candidozyma auris, a deadly drug-resistant fungus that has increased by 67% in European hospitals year-over-year. - The European Centre for Disease Prevention and Control reported 1,346 C. auris cases in 2023, representing a nearly 400% increase from 2020 levels, with mortality rates reaching up to 60% within 90 days. - Single C. auris outbreaks can cost healthcare systems over €1 million in containment and treatment expenses, while the fungus resists most disinfectants and survives on surfaces for extended periods. - Steriwave is already deployed in Canadian hospitals and NHS trusts in the UK, offering a non-invasive therapy that applies photosensitive agents to nostrils before red light illumination kills pathogens.
- King's College Hospital will pilot Ondine Biomedical's Steriwave technology as part of a quality improvement initiative to prevent hospital-acquired infections (HAIs). - Steriwave uses a light-activated agent to eliminate infection-causing pathogens in a rapid, five-minute treatment, offering an alternative to antibiotics. - Mid Yorkshire Teaching NHS Trust adopted Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients in March 2024. - Steriwave's accessibility has increased across England and Wales after its addition to the NHS Supply Chain in June 2024, facilitating broader adoption.
